Regeneron and Gilead Sciences Are Witnessing Consistent Progress on Coronavirus Treatments
The coronavirus crisis may have created turmoil in the markets over the past week or so, but that is not the case with all stocks. Many companies that are involved in creating medicines and vaccines for the virus have seen their stocks soar. However, two companies, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Gilead Sciences, Inc. (NASDAQ: GILD), have seen their stocks performed badly despite having made progress with coronavirus treatments.
On Monday, both those stock had recorded declines in excess of 4% and the is perhaps an indication that despite the progress made by the companies, the market remains doubtful about its products.
According to analyst Geoffrey Porges, the antiviral drug named Remedisivir, which had been developed by Gilead for the Ebola virus is one of the more promising coronavirus products in the market. Gilead is going to conduct studies in China regarding the same.
On the other hand, Regeneron is also in the process of developing preventive medicines as well as antibodies for the coronavirus. Investors could do well to keep an eye on those stocks as the coronavirus crisis deepens worldwide.
If investors are indeed looking for promising stocks at this point, then they could do well to have a closer look at CBD Unlimited Inc’s (OTC: EDXC) stock.
CBD Unlimited Inc. (OTC: EDXC) is involved in hemp-based CBD and has created products like oils, tropicals, and pet products, among others. The highest selling product for CBD Unlimited Inc. (OTC: EDXC) is the Phyto Bites chew meant for pets. However, the company is also working on a wide range of other products.
The research and development arm of CBD Unlimited is particularly well known for having managed to be highly accurate with the CBD dosage. It is perhaps one of the most important aspects of any CBD product manufacturer, and CBD Unlimited Inc. (OTC: EDXC) has managed to become an expert in that.
Last week, CBD Unlimited Inc. (OTC: EDXC) announced that it acquired New York-based cannabis brand-building firm Kush Co. CBD Unlimited Inc. (OTC: EDXC) revealed that the growing demand for CBD based products prompted it to acquire a brand-building company.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com
Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
